Direct agonist activity of tricyclic antidepressants at distinct opioid receptor subtypes

Journal of Pharmacology and Experimental Therapeutics

Volumn 332, Issue 1, 2010, Pages 255-265

  Onali, Pierluigi ^a   Dedoni, Simona ^a   Olianas, Maria C ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; ADENYLATE CYCLASE; AMITRIPTYLINE; AMOXAPINE; CYCLIC AMP; DELTA OPIATE RECEPTOR; DESIPRAMINE; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); GUANOSINE 5' O (3 THIOTRIPHOSPHATE) SULFUR 35; IMIPRAMINE; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR ANTAGONIST; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MU OPIATE RECEPTOR; NALTRINDOLE; NORBINALTORPHIMINE; NORTRIPTYLINE; OPIATE RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL STIMULATION; CHO CELL; CONTROLLED STUDY; CORPUS STRIATUM; DORSAL ROOT; DRUG BINDING; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; FRONTAL CORTEX; GLIOMA CELL; HUMAN; HUMAN CELL; MOLECULE; NEUROTRANSMISSION; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR AFFINITY; SIGNAL TRANSDUCTION;

ADULT; AGED; ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CELL LINE, TUMOR; CELL MEMBRANE; CHO CELLS; CORPUS STRIATUM; CRICETINAE; CRICETULUS; CYCLIC AMP; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FRONTAL LOBE; HUMANS; MALE; MIDDLE AGED; NUCLEUS ACCUMBENS; PROTEIN BINDING; RADIOLIGAND ASSAY; RATS; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU;

EID: 73949132158     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.159939     Document Type: Article

References (40)

1. Baldessarini RJ (2006) Drug therapy of depression and anxiety disorders, in Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th ed (Brunton LL, Lazo JS, and Parker KL eds) pp 429-459, McGraw-Hill Book Companies, New York.
2. Benbouzid M, Choucair-Jaafar N, Yalcin I, Waltisperger E, Muller A, Freund-Mercier MJ, and Barrot M (2008a) Chronic, but not acute, tricyclic antidepressant treatment alleviates neuropathic allodynia after sciatic nerve cuffing in mice. Eur J Pain 12:1008-1017.
3. Benbouzid M, Gavériaux-Ruff C, Yalcin I, Waltisperger E, Tessier LH, Muller A, Kieffer BL, Freund-Mercier MJ, and Barrot M (2008b) Delta-opioid receptors are critical for tricyclic antidepressant treatment of neuropathic allodynia. Biol Psychiatry 63:633-636.
4. Besson A, Privat AM, Eschalier A, and Fialip J (1999) Dopaminergic and opioidergic mediations of tricyclic antidepressants in the learned helplessness paradigm. Pharmacol Biochem Behav 64:541-548.
5. Biegon A and Samuel D (1980) Interaction of tricyclic antidepressants with opiate receptors. Biochem Pharmacol 29:460-462.
6. Bohn LM, Belcheva MM, and Coscia CJ (2000) Mitogenic signaling via endogenous κ-opioid receptors in C6 glioma cells: evidence for the involvement of protein kinase C and the mitogen-activated protein kinase signaling cascade. J Neurochem 74:564-573.
7. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
8. Chen F and Lawrence AJ (2004) Chronic antidepressant treatment causes a selective reduction of μ-opioid receptor binding and functional coupling to G proteins in the amygdale of Fawn-Hooded rats. J Pharmacol Exp Ther 310:1020-1026.
9. De Felipe MC, De Ceballos ML, Gil C, and Fuentes JA (1985) Chronic antidepressant treatment increases enkephalin levels in n. accumbens and striatum of the rat. Eur J Pharmacol 112:119-122.
10. Devoize JL, Rigal F, Eschalier A, and Trolese JF (1982) Naloxone inhibits clomipramine in mouse forced swimming test. Eur J Pharmacol 78:229-231.
11. Duman CH, Schlesinger L, Kodama M, Russell DS, and Duman RS (2007) A role for MAP kinase signaling in behavioral models of depression and antidepressant treatment. Biol Psychiatry 61:661-670.
12. Duman RS, Malberg J, Nakagawa S, and D'Sa C (2000) Neuronal plasticity and survival in mood disorders. Biol Psychiatry 48:732-739.
13. Filliol D, Ghozland S, Chluba J, Martin M, Matthes HW, Simonin F, Befort K, Gavériaux-Ruff C, Dierich A, LeMeur M, et al. (2000) Mice deficient for δ- and μ-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet 25:195-200.
14. Glotzbach RK and Preskorn SH (1982) Brain concentrations of tricyclic antidepressants: single-dose kinetics and relationship to plasma concentrations in chronically dosed rats. Psychopharmacology 78:25-27.
15. Gray AM, Spencer PS, and Sewell RD (1998) The involvement of the opioidergic system in the antinociceptive mechanisms of action of antidepressant compounds. Br J Pharmacol 124:669-674.
16. Hall H and Ogren SO (1981) Effects of antidepressant drugs on different receptors in the brain. Eur J Pharmacol 70:393-407.
17. Hamon M, Gozlan H, Bourgoin S, Benoliel JJ, Mauborgne A, Taquet H, Cesselin F, and Mico JA (1987) Opioid receptors and neuropeptides in the CNS in rats treated chronically with amoxapine or amitriptyline. Neuropharmacology 26:531-539.
18. Herman ZS, Obuchowicz E, Kowalski J, and Plech A (1986) Leu-enkephalin content in rat brain during prolonged treatment with imipramine or amitriptyline. Neuropeptides 7:113-124.
19. Hisaoka K, Takebayashi M, Tsuchioka M, Maeda N, Nakata Y, and Yamawaki S (2007) Antidepressants increase glial cell line-derived neurotrophic factor production through monoamine-independent activation of protein tyrosine kinase and extracellular signal-regulated kinase in glial cells. J Pharmacol Exp Ther 321: 148-157.
20. Isenberg KE and Cicero TJ (1984) Possible involvement of opiate receptors in the pharmacological profiles of antidepressant compounds. Eur J Pharmacol 103: 57-63.
21. Jope RS and Roh MS (2006) Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr Drug Targets 7:1421-1434.
22. Jutkiewicz EM (2006) The antidepressant-like effects of delta-opioid receptor agonists. Mol Interv 6:162-169.
23. Kobayashi A, Fujita K, and Nakazawa K (1992) In rat brain amoxapine enhances dopamine metabolism: pharmacokinetic variations of the effect. Eur J Pharmacol 215:43-49.
24. Kurumaji A, Mitsushio H, and Takashima M (1988) Chronic dietary treatment with antidepressants decrease brain Met-enkephalin-like immunoreactivity in the rat. Psychopharmacology 94:188-192.
25. Litovitz TL and Troutman WG (1983) Amoxapine overdose. Seizures and fatalities. JAMA 250:1069-1071.
26. Loacker S, Sayyah M, Wittmann W, Herzog H, and Schwarzer C (2007) Endogenous dynorphin in epileptogenesis and epilepsy: anticonvulsant net effect via kappa opioid receptors. Brain 130:1017-1028.
27. Mague SD, Pliakas AM, Todtenkopf MS, Tomasiewicz HC, Zhang Y, Stevens WC Jr, Jones RM, Portoghese PS, and Carlezon WA Jr (2003) Antidepressant-like effects of κ-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther 305:323-330.
28. Marchand F, Ardid D, Chapuy E, Alloui A, Jourdan D, and Eschalier A (2003) Evidence for an involvement of supraspinal δ- and spinal μ-opioid receptors in the antihyperalgesic effect of chronically administered clomipramine in mononeuropathic rats. J Pharmacol Exp Ther 307:268-274.
29. McLaughlin JP, Marton-Popovici M, and Chavkin C (2003) κ-Opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J Neurosci 23:5674-5683.
30. Metcalf MD and Coop A (2005) Kappa opioid antagonists: past successes and future prospects. AAPS J 7:E704-E722.
31. Micó JA, Ardid D, Berrocoso E, and Eschalier A (2006) Antidepressants and pain. Trends Pharmacol Sci 27:348-354.
32. Narita M, Kuzumaki N, Miyatake M, Sato F, Wachi H, Seyama Y, and Suzuki T (2006) Role of δ-opioid receptor function in neurogenesis and neuroprotection. J Neurochem 97:1494-1505.
33. Olianas MC, Concas D, and Onali P (2006) Agonist activity of naloxone benzoylhydrazone at recombinant and native opioid receptors. Br J Pharmacol 147:360-370.
34. Olianas MC, Maullu C, and Onali P (1999) Mixed agonist-antagonist properties of clozapine at different human cloned muscarinic receptor subtypes expressed in Chinese hamster ovary cells. Neuropsychopharmacology 20:263-270.
35. Stengaard-Pedersen K and Schou M (1986) Opioid receptors in the brain of the rat following chronic treatment with desipramine and electroconvulsive shock. Neuropharmacology 25:1365-1371.
36. Tegeder I and Geisslinger G (2004) Opioids as modulators of cell death and survival - unraveling mechanisms and revealing new indications. Pharmacol Rev 56:351-369.
37. Tejedor-Real P, Mico JA, Maldonado R, Roques BP, and Gibert-Rahola J (1995) Implication of endogenous opioid system in the learned helplessness model of depression. Pharmacol Biochem Behav 52:145-152.
38. Wahlström A, Lenhammar L, Ask B, and Rane A (1994) Tricyclic antidepressants inhibit opioid receptor binding in human brain and hepatic morphine glucuronidation. Pharmacol Toxicol 75:23-27.
39. Wall PM and Messier C (2000) U-69,593 microinjection in the infralimbic cortex reduces anxiety and enhances spontaneous alternation memory in mice. Brain Res 856:259-280.
40. s6k S6 kinase. Biochem J 325:217-222.